25 May 2016 -  These agents are anticipated to bring more treatment options for patients, along with significant cost savings. But are clinicians ready for them?

Medscape asked Leah Christl, PhD, associate director for therapeutic biologics in the Center for Drug Evaluation and Research at the FDA, to address the key issues they want healthcare professionals to understand.

For more details, go to: http://www.medscape.com/viewarticle/863411